CA2408349A1 - Method of regulating angiogenesis unsing ryk protein - Google Patents

Method of regulating angiogenesis unsing ryk protein Download PDF

Info

Publication number
CA2408349A1
CA2408349A1 CA002408349A CA2408349A CA2408349A1 CA 2408349 A1 CA2408349 A1 CA 2408349A1 CA 002408349 A CA002408349 A CA 002408349A CA 2408349 A CA2408349 A CA 2408349A CA 2408349 A1 CA2408349 A1 CA 2408349A1
Authority
CA
Canada
Prior art keywords
seq
protein
leu
ryk
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002408349A
Other languages
English (en)
French (fr)
Inventor
Steve Roczniak
Nathalie A. Dubois-Stringfellow
Alya Zolotorev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2408349A1 publication Critical patent/CA2408349A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002408349A 2000-05-10 2001-05-09 Method of regulating angiogenesis unsing ryk protein Abandoned CA2408349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10
US09/568,783 2000-05-10
PCT/US2001/015043 WO2001085789A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis

Publications (1)

Publication Number Publication Date
CA2408349A1 true CA2408349A1 (en) 2001-11-15

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002408349A Abandoned CA2408349A1 (en) 2000-05-10 2001-05-09 Method of regulating angiogenesis unsing ryk protein

Country Status (13)

Country Link
EP (1) EP1287121A2 (enExample)
JP (1) JP2004527206A (enExample)
AR (1) AR028424A1 (enExample)
AU (1) AU2001261343A1 (enExample)
CA (1) CA2408349A1 (enExample)
CO (1) CO5300464A1 (enExample)
DO (1) DOP2001000164A (enExample)
EC (1) ECSP014068A (enExample)
GT (1) GT200100079A (enExample)
PE (1) PE20011218A1 (enExample)
SV (1) SV2002000442A (enExample)
UY (1) UY26696A1 (enExample)
WO (1) WO2001085789A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516608A (ja) * 2002-02-06 2005-06-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング エネルギー恒常性の調節に関与するキナーゼ
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶(ryk)抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107472A (en) * 1992-05-11 2000-08-22 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
EP1084245B1 (en) * 1998-06-11 2006-03-29 AstraZeneca AB Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
PE20011218A1 (es) 2002-02-01
SV2002000442A (es) 2002-07-03
EP1287121A2 (en) 2003-03-05
AU2001261343A1 (en) 2001-11-20
GT200100079A (es) 2001-12-31
ECSP014068A (es) 2002-02-25
UY26696A1 (es) 2001-12-28
DOP2001000164A (es) 2002-05-15
WO2001085789A2 (en) 2001-11-15
AR028424A1 (es) 2003-05-07
JP2004527206A (ja) 2004-09-09
WO2001085789A3 (en) 2002-05-16
CO5300464A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
RU2727165C2 (ru) Слитый полипептид с противораковой активностью
EP1414964B1 (en) Vegf isoform
EP1469878B1 (en) Fgfr agonists
US6413726B1 (en) Antibodies that specifically bind Cytostatin III
US20100190838A1 (en) Connective Tissue Growth Factor Fragments and Methods and Uses Thereof
US8168593B2 (en) Mutated netrin-4, fragments thereof and their use as medicines
JP2002516103A (ja) インターロイキン21およびインターロイキン22
US20100158907A1 (en) Connective tissue growth factor fragments and methods and uses thereof
KR20120108046A (ko) 오스테오프로테게린 결합 단백질 및 이를 코드하는 핵산
JP2001520039A (ja) ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
KR20000049207A (ko) 섬유아세포 성장인자 상동체
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
JP2002531127A (ja) 成長因子相同体zvegf3
US8420780B2 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
US20040023864A1 (en) Method of regulating angiogenesis using ryk protein
CA2408349A1 (en) Method of regulating angiogenesis unsing ryk protein
EP1578907A2 (en) Secreted protein, ztnf9
JP2001511648A (ja) 樹状細胞由来成長因子
JP3989589B2 (ja) 血管細胞調節剤
US5866693A (en) DNA encoding human MAD proteins
CA2317812A1 (en) Human growth factor homologs
US20040086501A1 (en) Protein having activity as an angiogenesis modulator
CN100443501C (zh) 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途
US7122342B1 (en) Protease-activated receptor PAR4 (ZCHEMR2)
AU711647B2 (en) Fibroblast growth factor 15

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead